Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Phillips AN, et al. Among authors: dunn d. AIDS. 2005 Mar 25;19(5):487-94. doi: 10.1097/01.aids.0000162337.58557.3d. AIDS. 2005. PMID: 15764854
HIV/HCV coinfection, HAART, and liver-related mortality.
Sabin CA, Walker AS, Dunn D. Sabin CA, et al. Among authors: dunn d. Lancet. 2004 Aug 28-Sep 3;364(9436):757-8; author reply 758. doi: 10.1016/S0140-6736(04)16930-4. Lancet. 2004. PMID: 15337398 No abstract available.
A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators.
Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, McCormack S, Babiker AG, Darbyshire JH; Evaluation of Resistance Assays (ERA) Trial Investigators. Dunn DT, et al. J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):553-9. doi: 10.1097/01.qai.0000148533.12329.96. J Acquir Immune Defic Syndr. 2005. PMID: 15793365 Clinical Trial.
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study Steering Committee. Easterbrook PJ, et al. Among authors: dunn dt. HIV Med. 2008 Jan;9(1):47-56. doi: 10.1111/j.1468-1293.2008.00512.x. HIV Med. 2008. PMID: 18199172 Free article.
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?
Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, Phillips A, Allen E, Pillay D; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC). Grover D, et al. Among authors: dunn dt. J Antimicrob Chemother. 2008 Mar;61(3):705-13. doi: 10.1093/jac/dkm522. Epub 2008 Jan 25. J Antimicrob Chemother. 2008. PMID: 18222956
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.
Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H, Tookey P, Butler K, Sabin CA, Gibb D, Pillay D; Collaborative HIV Paediatric Study; UK Collaborative Group on HIV Drug Resistance. Chakraborty R, et al. Among authors: dunn d. Pediatr Infect Dis J. 2008 May;27(5):457-9. doi: 10.1097/INF.0b013e3181646d6f. Pediatr Infect Dis J. 2008. PMID: 18382385
1,725 results